JP2023518538A5 - - Google Patents

Info

Publication number
JP2023518538A5
JP2023518538A5 JP2022555951A JP2022555951A JP2023518538A5 JP 2023518538 A5 JP2023518538 A5 JP 2023518538A5 JP 2022555951 A JP2022555951 A JP 2022555951A JP 2022555951 A JP2022555951 A JP 2022555951A JP 2023518538 A5 JP2023518538 A5 JP 2023518538A5
Authority
JP
Japan
Prior art keywords
sequence
sequence number
lcvr
hcvr
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022555951A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023518538A (ja
JP7796034B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/057132 external-priority patent/WO2021186056A1/en
Publication of JP2023518538A publication Critical patent/JP2023518538A/ja
Publication of JP2023518538A5 publication Critical patent/JP2023518538A5/ja
Application granted granted Critical
Publication of JP7796034B2 publication Critical patent/JP7796034B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022555951A 2020-03-20 2021-03-19 ヒトcd45rcに特異的なキメラ抗原受容体およびその使用 Active JP7796034B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20305298 2020-03-20
EP20305298.0 2020-03-20
PCT/EP2021/057132 WO2021186056A1 (en) 2020-03-20 2021-03-19 Chimeric antigen receptor specific for human cd45rc and uses thereof

Publications (3)

Publication Number Publication Date
JP2023518538A JP2023518538A (ja) 2023-05-02
JP2023518538A5 true JP2023518538A5 (cg-RX-API-DMAC7.html) 2024-03-27
JP7796034B2 JP7796034B2 (ja) 2026-01-08

Family

ID=71465223

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022555951A Active JP7796034B2 (ja) 2020-03-20 2021-03-19 ヒトcd45rcに特異的なキメラ抗原受容体およびその使用

Country Status (11)

Country Link
US (1) US20230147657A1 (cg-RX-API-DMAC7.html)
EP (1) EP4121457A1 (cg-RX-API-DMAC7.html)
JP (1) JP7796034B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230004510A (cg-RX-API-DMAC7.html)
CN (1) CN115916823A (cg-RX-API-DMAC7.html)
AU (1) AU2021237790A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022018795A2 (cg-RX-API-DMAC7.html)
CA (1) CA3172120A1 (cg-RX-API-DMAC7.html)
IL (1) IL296546A (cg-RX-API-DMAC7.html)
MX (1) MX2022011683A (cg-RX-API-DMAC7.html)
WO (1) WO2021186056A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230032871A1 (en) * 2021-07-14 2023-02-02 Innovative Cellular Therapeutics Holdings, Ltd. Recombinant Viral Particle for Gene and/or Cellular Therapy
EP4719352A1 (en) 2023-05-31 2026-04-08 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ,インコーポレイティド 人工抗体ポリペプチド
EP1235842A4 (en) 1999-10-15 2003-04-23 Univ Massachusetts Rna interference pathway genes as tools for targeted genetic interference
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
HK1052372A1 (zh) 2000-02-24 2003-09-11 Xcyte Therapies, Inc. 细胞的同步刺激和富集
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
WO2001096584A2 (en) 2000-06-12 2001-12-20 Akkadix Corporation Materials and methods for the control of nematodes
US7745140B2 (en) 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
WO2004094642A2 (en) 2003-04-24 2004-11-04 Fondazione Centro San Raffaele Del Monte Tabor Lentiviral vectors carrying synthetic bi-directional promoters and uses thereof
AU2005250408B2 (en) 2004-05-27 2010-09-23 The Trustees Of The University Of Pennsylvania Novel artificial antigen presenting cells and uses therefor
US20070036773A1 (en) 2005-08-09 2007-02-15 City Of Hope Generation and application of universal T cells for B-ALL
AU2006294644A1 (en) 2005-09-27 2007-04-05 Amunix, Inc. Proteinaceous pharmaceuticals and uses thereof
GB0603081D0 (en) 2006-02-15 2006-03-29 Dynal Biotech Asa Oslo Method
WO2011059836A2 (en) 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
US8956828B2 (en) 2009-11-10 2015-02-17 Sangamo Biosciences, Inc. Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
CA2805442C (en) 2010-07-21 2020-05-12 Sangamo Biosciences, Inc. Methods and compositions for modification of an hla locus
EP3459560B1 (en) 2011-04-08 2021-02-24 The United States of America, as represented by The Secretary, Department of Health and Human Services Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer
ES2728782T3 (es) 2012-05-25 2019-10-28 Univ California Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN
CN105209621B (zh) 2012-12-12 2021-05-25 布罗德研究所有限公司 对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
KR102955556B1 (ko) 2012-12-12 2026-04-22 더 브로드 인스티튜트, 인코퍼레이티드 서열 조작을 위한 crispr-cas 성분 시스템, 방법 및 조성물
US20170226209A1 (en) 2014-08-01 2017-08-10 INSERM (Institut National de la Santé et de la Recherche Médicale) An anti-cd45rc antibody for use as drug
US20180334490A1 (en) * 2014-12-03 2018-11-22 Qilong H. Wu Methods for b cell preconditioning in car therapy
US20180251731A1 (en) * 2015-09-07 2018-09-06 INSERM (Institute National de la Santé et de la Recherche Médicale) Subpopulation of cd8+cd45rclow tregs and uses thereof
SG11201807489PA (en) * 2016-03-04 2018-09-27 Novartis Ag Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
EP3652306A1 (en) * 2017-07-13 2020-05-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for increasing expansion and immunosuppressive capacity of a population of cd8+cd45rclow/-tregs
EP3498293A1 (en) 2017-12-15 2019-06-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Treatment of monogenic diseases with an anti-cd45rc antibody
EP3626265A1 (en) * 2018-09-21 2020-03-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-human cd45rc antibodies and uses thereof

Similar Documents

Publication Publication Date Title
US10815302B2 (en) Anti-PD-1 antibody and use thereof
KR102236259B1 (ko) 항-lag-3 항체 및 그것의 사용
EP3476399B1 (en) Lag-3 antibody, antigen-binding fragment thereof, and pharmaceutical application thereof
US7524498B2 (en) Human immunomodulatory monoclonal antibodies for the treatment of cancer
Gorman et al. Reshaping a therapeutic CD4 antibody.
KR102153374B1 (ko) 인간 항-cd27 항체, 방법 및 용도
TWI614267B (zh) 抗人類cd52免疫球蛋白
US7829086B2 (en) Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
US8664363B2 (en) Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
WO2020043188A1 (zh) 抗cd47抗体及其应用
CA2819520C (en) Anti cd4 antibodies to prevent in particular graft-versus-host-disease (gvhd)
CN109651507B (zh) 一种激动型4-1bb单克隆抗体
CN108124445A (zh) Ctla4抗体、其药物组合物及其用途
TR201807202T4 (tr) CD70 antikorları.
JP2018520667A (ja) ヒトhlaにより提示されるebv潜伏感染膜タンパク質2aペプチドに特異的なt細胞受容体様抗体剤
JP2014532074A5 (cg-RX-API-DMAC7.html)
WO2023193662A1 (zh) 靶向bcma的嵌合抗原受体及其应用
CN110790839B (zh) 抗pd-1抗体、其抗原结合片段及医药用途
CN116789820A (zh) 一种新型免疫调节剂的开发和应用
WO2023036326A1 (zh) 抗人cd3抗体及其应用
WO2024017362A1 (zh) 靶向gprc5d和/或bcma的嵌合抗原受体及其应用
JP2026506623A (ja) 抗cdh6抗体及びその使用
CN116854820B (zh) Pd-1非阻断性清除抗体及其用途
JP2023543835A5 (cg-RX-API-DMAC7.html)
Wu et al. Characterization of a humanized anti-CD20 antibody with potent antitumor activity against B-cell lymphoma